Updates are available Correction dated 2025-11-26

Article History

Received: 30 April 2025

Accepted: 24 September 2025

First Online: 13 October 2025

Change Date: 26 November 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13555-025-01593-x

Declarations

:

: Mark Lebwohl has served as a consultant and/or received research funds from AbbVie, Almirall, AltruBio Apogee, Arcutis, AstraZeneca, Atomwise, Avotres, Bristol Myers Squibb, Boehringer Ingelheim, Cara, Castle, Celltrion, Clexio, Dermavant, Evommune, Facilitation of International Dermatology Education, Forte, Galderma, Genentech, Incyte, Inozyme, Janssen, LEO Pharma, Lilly, Meiji Seika, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, UCB, and Verrica. Mark Lebwohl is an editorial board member of Dermatology and Therapy. Mark Lebwohl was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. Emma Yue, Whitney S. Krueger, and Ayman Grada were or are full-time employees of AbbVie, and may hold AbbVie stock and/or stock options. Brian Berman has served as consultant and/or investigator for AbbVie, Aiviva, Almirall, Anacor, Biofrontera, Birch BioMed, BPG Bio, Bristol Myers Squibb, Castle Ferndale, FBM, Galderma, GSK, Lemonex, Mediwound, Minolabs, Novan, Novartis, Ortho Dermatologics/Valeant, Pfizer, PHD Biosciences, Pulse, Sensus, Sirnanomics, Smith & Nephew, Sun Pharma, and Thirona. Christopher G. Bunick has served as an investigator, consultant, and/or speaker for AbbVie, Allergan, Almirall, Apogee, Arcutis, Daiichi Sankyo, EPI Health/Novan, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Palvella, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, Timber, and UCB. Todd Schlesinger has served as an advisor, investigator, and consultant for AbbVie, Allergan (an AbbVie Company), Almirall, Amgen, Alumis, Apogee, Arcutis, ASLAN, Benev, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermsquared, Eli Lilly and Company, ExoCoBio, Flint Clinical, Galderma, Genentech, Highlightll, HTL Biotechnologies, Incyte, Janssen, L’Oreal, Novartis, Pfizer Inc., RBC Consultants, Regeneron, Rion, Sanofi, SiSaf, Sun Pharma, Takeda, UCB, and Verrica, and has received a salary from Avant-Health.

: This was a noninterventional study that used de-identified secondary data from a commercially available claims database and posed no risk to patients. No institutional review board review or approval was necessary. The study was conducted in accordance with all legal and regulatory requirements.